Your browser doesn't support javascript.
loading
Does recipient body mass index inform donor selection for allogeneic haematopoietic cell transplantation?
Abou-Ismail, Mouhamed Yazan; Fraser, Raphael; Allbee-Johnson, Mariam; Metheny, Leland; Ravi, Gayathri; Ahn, Kwang Woo; Bhatt, Neel S; Lazarus, Hillard M; de Lima, Marcos; El Jurdy, Najla; Hematti, Peiman; Beitinjaneh, Amer M; Nishihori, Taiga; Badawy, Sherif M; Sharma, Akshay; Pasquini, Marcelo C; Savani, Bipin N; Sorror, Mohamed L; Stadtmauer, Edward A; Chhabra, Saurabh.
Afiliação
  • Abou-Ismail MY; Division of Hematology & Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
  • Fraser R; CIBMTR® (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
  • Allbee-Johnson M; Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, WI, USA.
  • Metheny L; CIBMTR® (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
  • Ravi G; Adult Hematologic Malignancies & Stem Cell Transplant Section, Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
  • Ahn KW; Division of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
  • Bhatt NS; CIBMTR® (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
  • Lazarus HM; Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, WI, USA.
  • de Lima M; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • El Jurdy N; University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH, USA.
  • Hematti P; The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH, USA.
  • Beitinjaneh AM; The Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN, USA.
  • Nishihori T; Division of Hematology/Oncology/Bone Marrow Transplantation, Department of Medicine, University of Wisconsin, Madison, WI, USA.
  • Badawy SM; Division of Transplantation and Cellular Therapy, University of Miami Hospital and Clinics, Sylvester Comprehensive Cancer Center, Miami, FL, USA.
  • Sharma A; Department of Blood & Marrow Transplant and Cellular Immunotherapy (BMT CI), Moffitt Cancer Center, Tampa, FL, USA.
  • Pasquini MC; Division of Hematology, Oncology and Stem Cell Transplant, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA.
  • Savani BN; Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
  • Sorror ML; Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, TN, USA.
  • Stadtmauer EA; CIBMTR® (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
  • Chhabra S; Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
Br J Haematol ; 197(3): 326-338, 2022 05.
Article em En | MEDLINE | ID: mdl-35286719
ABSTRACT
It is not known whether obesity has a differential effect on allogeneic haematopoietic cell transplantation outcomes with alternative donor types. We report the results of a retrospective registry study examining the effect of obesity [body mass index (BMI) > 30] on outcomes with alternative donors (haploidentical related donor with two or more mismatches and receiving post-transplant cyclophosphamide [haplo] and cord blood (CBU)] versus matched unrelated donor (MUD). Adult patients receiving haematopoietic cell transplantation for haematologic malignancy (2013-2017) (N = 16 182) using MUD (n = 11 801), haplo (n = 2894) and CBU (n = 1487) were included. The primary outcome was non-relapse mortality (NRM). The analysis demonstrated a significant, non-linear interaction between pretransplant BMI and the three donor groups for NRM NRM risk was significantly higher with CBU compared to haplo at BMI 25-30 [hazard ratio (HR) 1.66-1.71, p < 0.05] and MUD transplants at a BMI of 25-45 (HR, 1.61-3.47, p < 0.05). The results demonstrated that NRM and survival outcomes are worse in overweight and obese transplant recipients (BMI ≥ 25) with one alternative donor type over MUD, although obesity does not appear to confer a uniform differential mortality risk with one donor type over the other. BMI may serve as a criterion for selecting a donor among the three (MUD, haplo and CBU) options, if matched sibling donor is not available.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas / Doença Enxerto-Hospedeiro Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas / Doença Enxerto-Hospedeiro Idioma: En Ano de publicação: 2022 Tipo de documento: Article